Wire · opportunities
Regeneron Pharmaceuticals Announces FDA Approval of Pasatru for Adults With ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 August 2026 · Fusion42 review
The FDA has approved Pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder causing abnormal bone growth. Pasatru, a monoclonal antibody blocking Activin A, demonstrated over 90% reduction in new heterotopic ossification lesions and flare-ups in the OPTIMA Phase 3 trial.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 19 Aug 2026 and 31 Aug 2026.
◆ ◆ The Wire takeaway
You have a rare disease treatment with FDA green light that can be given beyond specialised clinics, including at home. This opens access pathways and pushes you to plan for patient support and insurance navigation now.
◆ Coverage
8 sources · first reported 19 Aug 2026 · latest 31 Aug 2026
◆ Topics